Allogene’s evolving allogeneic CAR-T approach is advancing under a FDA Regenerative Medicine Advanced Therapy (RMAT) designation, after the company reported encouraging interim data as it enrolls the 24th patient in an ongoing study aimed at delaying relapse in susceptible lymphoma patients. The program also includes early readouts in clear-cell renal carcinoma, with the company continuing to manage immune-effector toxicity risks across the platform.